TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01812616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sativex
Description: Administered orally as a spray to the cheek according to a standard dose titration regimen, until patients reach a maximum tolerated dose (maximum 12 sprays per day). Each spray delivers 100 μl (Δ9tetrahydrocannabinol (THC), 27 mg/ml: Cannabidiol (CBD), 25 mg/ml).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally as a spray to the cheek according to a standard dose titration regimen, until patients reach a maximum tolerated dose (maximum 12 sprays per day). Each spray delivers 100 μl ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring and Food, Drugs \& Cosmetics (FD\&C)certified color additives; FD\&C Yellow No.5 (E102 tartrazine) (0.0260%), FD\&C Yellow No.6 (E110 sunset yellow) (0.0038%), FD\&C Red No. 40 (E129 Allura red AC) (0.00330%) and FD\&C Blue No.1 (E133 Brilliant blue FCF) (0.00058%).
Study: NCT04282616

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based unstructured physical activity program
Description: Counselling on physical activity according to American College of Sports Medicine guidelines

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based structured low-intensity physical activity program
Description: Structured home-based low-intensity intermittent walking program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: In-hospital structured supervised physical activity program
Description: Supervised exercise training program
Study: NCT02254798

Intervention type: OTHER
Intervention: no intervention
Description: this is a non interventional study
Study: NCT02760121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methazolamide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04318262

Intervention type: BIOLOGICAL
Intervention: Determination of the clinical and biological characteristics
Description: * clinical data: types of infections (skin and soft tissues, bone and joint, bacteraemia, endocarditis...), delay between clinical signs and hospitalization, number of days of fever, number of days of hospitalization, infectious complications...~* biological data: Haemoglobin, Leucocytes, Neutrophils, Creatinine clearance, CRP...

Intervention type: BIOLOGICAL
Intervention: Determination of the clinical and biological characteristics
Description: * clinical data: types of infections (skin and soft tissues, bone and joint, bacteraemia, endocarditis...), delay between clinical signs and hospitalization, number of days of fever, number of days of hospitalization, infectious complications...~* biological data: Haemoglobin, Leucocytes, Neutrophils, Creatinine clearance, CRP...

Intervention type: BIOLOGICAL
Intervention: Determination of the clinical and biological characteristics
Description: * clinical data: types of infections (skin and soft tissues, bone and joint, bacteraemia, endocarditis...), delay between clinical signs and hospitalization, number of days of fever, number of days of hospitalization, infectious complications...~* biological data: Haemoglobin, Leucocytes, Neutrophils, Creatinine clearance, CRP...

Intervention type: BIOLOGICAL
Intervention: Description of the antibiotic resistance profile
Description: Determination of MICs of the major anti-staphylococcal antibiotics by the Sensititre technique

Intervention type: BIOLOGICAL
Intervention: Description of the antibiotic resistance profile
Description: Determination of MICs of the major anti-staphylococcal antibiotics by the Sensititre technique
Study: NCT00196391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DR-2021a
Description: 1 capsule daily for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DR-2021b
Description: 1 capsule daily for 10 days
Study: NCT04318262

Intervention type: BIOLOGICAL
Intervention: Description of the antibiotic resistance profile
Description: Determination of MICs of the major anti-staphylococcal antibiotics by the Sensititre technique

Intervention type: BIOLOGICAL
Intervention: Molecular epidemiology of S. lugdunensis infections
Description: Genome sequencing (Illumina technique)
Study: NCT01734083

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whole body vibration exercise
Description: The whole body vibration will be delivered by a platform that can generate vibration signals (Powerplate). The total duration of vibration exposure per session will range from 4 to 6 minutes. The vibration bouts (30-45 seconds per bout) will be interspersed with a 1 to 2 minutes of rest period. While standing on the vibration platform, subjects will be instructed to repeat two exercises: (1) static semi-squats, and (2) dynamic semi-squats.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional exercise
Description: The conventional exercise training will involve a combination of upper limb and lower limb stretching and strengthening exercises, balance training, and gait re-education.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conventional exercise
Description: The conventional exercise training will involve a combination of upper limb and lower limb stretching and strengthening exercises, balance training, and gait re-education.
Study: NCT00888290

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium bicarbonate
Description: Sodium bicarbonate at 3 different doses or placebo. The different doses tested will be: 0.3 mEq/kg of ideal body weight, 0.6 mEq/kg of ideal body weight and 1 mEq/kg pf ideal body weight

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo at 3 different doses to match Sodium bicarbonate dosing
Study: NCT00073645

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Peer/Group CBT
Description: Children will be trained to be more helpful and positive toward other children through role-playing activities.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family/Parents CBT
Description: Parents will be trained to manage their children's anxiety and avoidant behaviors by increasing acceptance and warmth toward their children.
Study: NCT00196391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DR-2021c
Description: 1 capsule daily for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DR-2021d
Description: 1 capsule daily for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DR-2021e
Description: 1 capsule daily for 10 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 matching placebo capsule for 10 days
Study: NCT00064142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: halofuginone hydrobromide
Description: Applied topically

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Applied topically

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: pharmacological study
Description: Correlative studies
Study: NCT04211077

Intervention type: OTHER
Intervention: Date collection
Description: Data collection from national SNIIRAM and PMSI database

Intervention type: OTHER
Intervention: Date collection
Description: Data collection from national SNIIRAM and PMSI database

Intervention type: OTHER
Intervention: Date collection
Description: Data collection from national SNIIRAM and PMSI database
Study: NCT00304772

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluconazole
Description: 400mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Micafungin
Description: 150mg/day
Study: NCT04250753

Intervention type: OTHER
Intervention: Walking task
Description: 30 meters walking task (15 meters round trip) following by a rest period of 2 minutes. Participants are invited to perform the 30 meters walking task twice. Inertial sensors are put on each participant foot.
Study: NCT01658020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zabofloxacin
Description: Zabofloxacin 367mg tablet P.O. once daily for 5days and then Placebo P.O. once daily for 2days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Moxifloxacin 400mg tablet P.O. once daily for 7days
Study: NCT04337671

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate intensity aerobic training
Description: The exercise program consisted of 5 minutes warm-up, 15-30 minutes of moderate aerobic exercises and 10 minutes cool-down, respectively.~Frequency: 3 sessions/week , and Duration:12 weeks.
Study: NCT03013140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluid therapy
Description: Goal directed Fluid therapy: Within 30 minutes before spinal anaesthesia, repeat Ringer's Injection 3ml/kg within 3 minutes with 1-min gap until ΔSV\<5%

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia
Description: Inject marcaine and fentanyl to CSF for anaesthesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal anaesthesia
Description: Inject marcaine and fentanyl to CSF for anaesthesia
Study: NCT02482610

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glucose
Description: Following baseline measurements, participants will consume a 75 g glucose solution within five minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose with Whole Fat Milk
Description: Following baseline measurements, participants will consume 75 g glucose dissolved in two cups of whole fat milk within five minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose with Non-fat Milk
Description: Following baseline measurements, participants will consume 75 g glucose dissolved in two cups of non-fat milk within five minutes.
Study: NCT01126697

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Coenzyme Q10 and Lisinopril
Description: Arm 1. Coenzyme Q10: taken once a day each morning by mouth OR Arm 2. Lisinopril: taken once a day each morning by mouth OR Arm 3. Coenzyme Q10 and lisinopril: each taken once a day in the morning by mouth OR Arm 4. Enhanced Standard Care (more doctor visits, muscle and breathing testing, and x-rays for monitoring, but no study medication).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Coenzyme Q10 and Lisinopril
Description: Arm 1. Coenzyme Q10: taken once a day each morning by mouth OR Arm 2. Lisinopril: taken once a day each morning by mouth OR Arm 3. Coenzyme Q10 and lisinopril: each taken once a day in the morning by mouth OR Arm 4. Enhanced Standard Care (more doctor visits, muscle and breathing testing, and x-rays for monitoring, but no study medication).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Coenzyme Q10 and Lisinopril
Description: Arm 1. Coenzyme Q10: taken once a day each morning by mouth OR Arm 2. Lisinopril: taken once a day each morning by mouth OR Arm 3. Coenzyme Q10 and lisinopril: each taken once a day in the morning by mouth OR Arm 4. Enhanced Standard Care (more doctor visits, muscle and breathing testing, and x-rays for monitoring, but no study medication).
Study: NCT01495910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: Abiraterone acetate oral suspension administered daily from study Day 1 to study Day 6 of each treatment period: the first dose level is 100 mg with escalating doses of 250 mg and 500 mg in subsequent treatment periods.
Study: NCT04507633

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ROMA therapy(reminiacence therpy, orientation, music, and art)
Description: An intervention comprising reminiscence of annual festivals, orientation, and familiar music listening and singing, and animation interaction to improve cognitive functions, depressive symptoms and behaviors problems.
Study: NCT04355936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan arm will receive 80 mg Telmisartan twice daily plus standard care.
Description: Control arm will receive standard care.
Study: NCT04886752

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: vitamin C without liposome
Description: subjects need to take 3 tests during trail. After each test was completed, a washout period of 14 days was required before the next test start
Study: NCT01338376

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured Education
Description: All of the educators who are responsible for the intensive group will be trained with the standard contents before the study kick-off.~* Educator Activities: insulin injection, SMBG instruction, self-learned manuals, periodic assessment for subjects, subject counseling, self-care education (healthy eating, exercise, weight control), prevention and treatment of hypoglycemia complication education ,newsletter delivered by SMS~* Physician Activity: frequent insulin titration

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Diabetes Education
Description: The activities of the educators who are responsible for conventional group are identical with their routine clinical practice.~* Educator Activities: insulin injection, SMBG instruction, healthy eating , prevention and treatment of hypoglycemia~* Physician Activity: less frequent insulin titration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Scilin®M30
Description: Subjects will be treated with Scilin®M30 twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Scilin®M30
Description: Subjects will be treated with Scilin®M30 twice daily
Study: NCT04886752

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: liposomal process A vitamin C
Description: subjects need to take 3 tests during trail. After each test was completed, a washout period of 14 days was required before the next test start

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: liposomal process B vitamin C (Double Nutri™)
Description: subjects need to take 3 tests during trail. After each test was completed, a washout period of 14 days was required before the next test start
Study: NCT04502992

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Acceptance and Committment Therapy
Description: Acceptance and Commitment Therapy (ACT) is a mindfulness-based therapy that focuses on enabling individuals to accept what is out of their control, and to commit to valued actions that enrich their lives (Vowles \& McCracken, 2008). By emphasizing acceptance instead of avoidance, ACT differs from many other forms of cognitive behavioral therapy. ACT has been shown to be efficacious in terms of clinical outcomes, adherence to treatment, and retention. ACT aims to increase psychological flexibility, and has been associated with improved health outcomes prior randomized controlled clinical trials, including three systematic reviews specific to CP. Psychological flexibility is defined as an individual's ability to recognize and adapt to various demands; shift mindsets or behavioral responses when these strategies compromise personal or social functioning; and maintain balance among important life domains.
Study: NCT02712970

Intervention type: PROCEDURE
Intervention: pit-picking technique
Description: midline pits were excised removing a minimal amount of tissue (with a margin of skin of \<1 mm). Incision of 1-2 cm in length was performed parallel to the most convenient side of the midline to be curetted of the chronic abscess cavity. All infected granulation tissue and hair were removed. After establishing hemostasis, the area of the excised midline pits was approximated by absorbable sutures.

Intervention type: PROCEDURE
Intervention: pit-picking technique
Description: midline pits were excised removing a minimal amount of tissue (with a margin of skin of \<1 mm). Incision of 1-2 cm in length was performed parallel to the most convenient side of the midline to be curetted of the chronic abscess cavity. All infected granulation tissue and hair were removed. After establishing hemostasis, the area of the excised midline pits was approximated by absorbable sutures.

Intervention type: PROCEDURE
Intervention: Bascom Cleft Lift
Description: The upper end of the incision was made 1-2 cm lateral to the midline on the more affected side and this was continued vertically over a distance of 1-2 mm from the midline pits. The lower end was fashioned from the midline in a V-shape in order to prevent a dog-ear deformity. The skin on this side of the natal cleft was then elevated and excised. The skin on the opposite side was undermined to the distance required to allow primary closure of the defect away from the midline without tension. Sinus tissue and its extensions were excised. The incision was then closed subcuticularly by absorbable polyglecaprone (3-0), after which a few interrupted mattress polyglecaprone (3-0) buttress sutures were also inserted.
Study: NCT01096680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD489 20 mg
Description: Single oral dose of 20 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD489 50 mg
Description: Single oral dose of 50 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD489 70 mg
Description: Single oral dose of 70 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Armodafinil
Description: Single oral dose of 250 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single oral dose
Study: NCT00497055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill manufactured to mimic Aripiprazole gel caps.
Study: NCT02696174

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HMI
Description: A defined priced package of primary care services, including investigation and treatment such as procedures and medication, available at a selected clinic for 6 months
Study: NCT01483599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 1959 (5 mg)
Description: Subcutaneous (SC) injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 1959 (15 mg)
Description: SC injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 1959 (50 mg)
Description: SC injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 1959 (100 mg)
Description: SC injections

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CNTO 1959 (100 mg)
Description: SC injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 1959 (200 mg)
Description: SC injections

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: SC injections

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SC injections
Study: NCT03634813

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Blood Pressure Monitor
Description: High Blood Pressure Monitoring device (Omron MX3 model BP742, Omron, Shaumberg, IL)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual Care
Study: NCT00673374

Intervention type: DEVICE
Intervention: radio-opaque adhesive skin markers
Description: The examining physician will place a radio-opaque skin marker (Beekley Corporation, Ortho-SPOTS® Order Code 187; 6mm spherical markers) at the point of maximal tenderness to direct abdominal palpation indicated by the patient. Additional markers will be placed at the cephalad and caudad limits of the region of tenderness, defined as the point at which the patient no longer complains of direct tenderness to palpation.
Study: NCT02712970

Intervention type: PROCEDURE
Intervention: Bascom Cleft Lift
Description: The upper end of the incision was made 1-2 cm lateral to the midline on the more affected side and this was continued vertically over a distance of 1-2 mm from the midline pits. The lower end was fashioned from the midline in a V-shape in order to prevent a dog-ear deformity. The skin on this side of the natal cleft was then elevated and excised. The skin on the opposite side was undermined to the distance required to allow primary closure of the defect away from the midline without tension. Sinus tissue and its extensions were excised. The incision was then closed subcuticularly by absorbable polyglecaprone (3-0), after which a few interrupted mattress polyglecaprone (3-0) buttress sutures were also inserted.

Intervention type: PROCEDURE
Intervention: Bascom Cleft Lift
Description: The upper end of the incision was made 1-2 cm lateral to the midline on the more affected side and this was continued vertically over a distance of 1-2 mm from the midline pits. The lower end was fashioned from the midline in a V-shape in order to prevent a dog-ear deformity. The skin on this side of the natal cleft was then elevated and excised. The skin on the opposite side was undermined to the distance required to allow primary closure of the defect away from the midline without tension. Sinus tissue and its extensions were excised. The incision was then closed subcuticularly by absorbable polyglecaprone (3-0), after which a few interrupted mattress polyglecaprone (3-0) buttress sutures were also inserted.

Intervention type: PROCEDURE
Intervention: Rhomboid excision with the Limberg Flap
Description: The area to be excised was mapped on the skin in a rhomboid form, and the flap was designed. The skin incision was deepened to the postsacral fascia. The flap was fully mobilized and transposed medially to fill the defect without tension. The wound was closed in two layers: the subcutaneous tissue with absorbable (2/0 polyglactin) sutures and the skin with nonabsorbable (3/0 polypropylene) interrupted mattress suture

Intervention type: PROCEDURE
Intervention: Rhomboid excision with the Limberg Flap
Description: The area to be excised was mapped on the skin in a rhomboid form, and the flap was designed. The skin incision was deepened to the postsacral fascia. The flap was fully mobilized and transposed medially to fill the defect without tension. The wound was closed in two layers: the subcutaneous tissue with absorbable (2/0 polyglactin) sutures and the skin with nonabsorbable (3/0 polypropylene) interrupted mattress suture

Intervention type: PROCEDURE
Intervention: Other flap techniques
Description: Bascom Cleft lift as described above, Rhomboid excision with the Limberg Flap as described above, V-Y advancement flap, Z-Plasty
Study: NCT01089296

Intervention type: OTHER
Group type: OTHER
Intervention: Individually customized physiotherapy
Description: Main elements in the intervention are postural support and facilitating techniques. The intervention will be carried out twice a day over a three-week period if the infant's condition allows it. The length of each treatment session will be adjusted dependent on the infant's response and condition. Maximum treatment time is 10 minutes.